Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrin Schöneweis

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Plos One|March 19, 2013
Proteoglycans act as cellular hepatitis delta virus attachment receptorsOscar Lamas Longarela, Tobias T Schmidt, Katrin Schöneweis, et al.
RNA (New York, N.Y.)|November 24, 2012
Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanismsSteffen Erkelenz, William F Mueller, Melanie S Evans, et al.
Scientific Reports|September 11, 2013
Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administrationRaphael J Gübeli, Katrin Schöneweis, Daniela Huzly, et al.
Ebiomedicine|August 29, 2016
Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B InfectionCarolin Cornelius, Katrin Schöneweis, Fanny Georgi, et al.
Antiviral Research|November 12, 2017
Activity of nucleic acid polymers in rodent models of HBV infectionKatrin Schöneweis, Neil Motter, Pia L Roppert, et al.
Nucleic Acids Research|January 1, 2017
Succession of splicing regulatory elements determines cryptic 5΄ss functionalityAnna-Lena Brillen, Katrin Schöneweis, Lara Walotka, et al.
Elife|July 24, 2019
Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptideDominik Witzigmann, Philipp Uhl, Sandro Sieber, et al.
Gastroenterology|February 8, 2018
HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of InterferonPascal Mutz, Philippe Metz, Florian A Lempp, et al.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Plos One|March 19, 2013
Proteoglycans act as cellular hepatitis delta virus attachment receptorsOscar Lamas Longarela, Tobias T Schmidt, Katrin Schöneweis, et al.
RNA (New York, N.Y.)|November 24, 2012
Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanismsSteffen Erkelenz, William F Mueller, Melanie S Evans, et al.
Scientific Reports|September 11, 2013
Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administrationRaphael J Gübeli, Katrin Schöneweis, Daniela Huzly, et al.
Ebiomedicine|August 29, 2016
Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B InfectionCarolin Cornelius, Katrin Schöneweis, Fanny Georgi, et al.
Antiviral Research|November 12, 2017
Activity of nucleic acid polymers in rodent models of HBV infectionKatrin Schöneweis, Neil Motter, Pia L Roppert, et al.
Nucleic Acids Research|January 1, 2017
Succession of splicing regulatory elements determines cryptic 5΄ss functionalityAnna-Lena Brillen, Katrin Schöneweis, Lara Walotka, et al.
Elife|July 24, 2019
Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptideDominik Witzigmann, Philipp Uhl, Sandro Sieber, et al.
Gastroenterology|February 8, 2018
HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of InterferonPascal Mutz, Philippe Metz, Florian A Lempp, et al.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Pageof 1